A recent study from the Dept of Cardiology, Harvard Medical School shows that “Cardiac-Specific YAP Activation Improves Cardiac Function and Survival in an Experimental Murine Myocardial Infarction Model.” This study was published in the prestigious Journal Circulation research by Prof Pu, Dr Lin and others from the Dept of Cardiology, Harvard Medical School; Cardiology, Children’s Hospital Boston; Genetics, Harvard Medical School etc.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Cardiovascular disorders: Natural product Cucurbitacin I (JSI-124) improves cardiac function and inhibits myocardial infarction via up regulation of its target gene. This study suggests that Cucurbitacin I (JSI-124), by increasing the expression of its target gene, it improves myocardial function. Together, this study suggests that pharmacological formulations containing” Cucurbitacin I (JSI-124) or its analogues” may be used to improve cardiac function.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for Cardiovascular disorders: Natural product Cucurbitacin I (JSI-124) improves cardiac function and inhibits myocardial infarction via up regulation of its target gene, 5/July/2014, 9.43 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation